CVR Medical Corp. (OTCQB:CRRVF)

VANCOUVER, BRITISH COLUMBIA, CANADA, September 13, 2017 /EINPresswire.com/ -- VANCOUVER, BC / ACCESSWIRE / September 11, 2017 / CVR Medical Corp. (TSX.V: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) is pleased to announce that an institutional research report has been released by RB Milestone Group, LLC (“RBMG”). The report on CVR Medical titled “Revolutionizing the Vascular Diagnostics Market” can be found on the website at www.CVRMed.com or by contacting Trevor Brucato, Managing Director at RBMG.

CVR Medical CEO Peter Bakema, speaking on the publishing of the research report, stated: “I am very pleased with the report and thoroughness of the analysis performed by the RB Milestone Group.”

RB Milestone Group, LLC (http://www.rbmilestone.com) is a New York based consulting firm that was engaged by CVR Medical to provide the report. They specialize in assisting small and venture-stage companies with enhancing corporate strategy, investor awareness, business development, market intelligence and research. RBMG partners with clients internationally and across a wide range of industry segments, including: healthcare, technology, energy, cleantech, mining, oil & gas, professional services and consumer goods. Staff specialists have diverse sector knowledge centered on capital markets.

For additional information on the organization, leadership, and current news please visit the company website at www.CVRMed.com.

About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Director

For further information contact:
RB Milestone Group, LLC
Trevor Brucato, Managing Director
tbrucato@rbmilestone.com

______________________________________________________________________________________________________________________

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Peter Bakema
1-734-718-5115
email us here
CVR Medical Corp.